Related Experiment Video
Updated: May 21, 2026
05:31
Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
Serum IL-23 in asthmatic children
G Ciprandi1, C Cuppari, A Salpietro
1Department of Internal Medicine, Azienda Ospedaliera Universitaria San Martino, Genoa, Italy.
Journal of Biological Regulators and Homeostatic Agents
|June 14, 2012
Summary
Inhaled corticosteroid treatment reduced serum IL-23 levels in children with allergic asthma, correlating with improved lung function. This suggests IL-23 may serve as a marker for allergic inflammation.
Area of Science:
- Immunology
- Pediatric Allergy
- Respiratory Medicine
Background:
- Asthma pathogenesis involves complex cytokine networks, including Th1/Th2 imbalance, Th17, and regulatory T (Treg) cells.
- Elevated Interleukin-4 (IL-4) and Interleukin-23 (IL-23) and reduced Interleukin-10 (IL-10) are implicated in allergic asthma.
Purpose of the Study:
- To investigate the effect of anti-inflammatory treatment on serum IL-4, IL-10, and IL-23 levels in children with asthma.
- To assess the relationship between these cytokine levels and lung function (FEV1) during treatment.
Main Methods:
- A study involving 78 children with house dust mite-sensitized asthma and 40 healthy controls.
- Measurements of lung function (FEV1) and serum IL-4, IL-10, and IL-23 at baseline, 4 weeks, and 12 weeks of inhaled corticosteroid (ICS) treatment.
Main Results:
- Baseline IL-4 and IL-23 were higher, while IL-10 was lower in asthmatic children compared to controls.
- ICS treatment significantly decreased IL-4 and IL-23 and increased IL-10 by 12 weeks.
- Significant correlations were observed between FEV1 and IL-4, IL-10, and IL-23 levels throughout the treatment period.
Conclusions:
- Serum IL-23 is upregulated in asthmatic children and is reduced by ICS treatment.
- Changes in IL-23 levels correlate with improvements in lung function, suggesting IL-23's potential as a marker for allergic inflammation in asthma.
Related Concept Videos
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: